Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity

Cancer Research

Volumn 73, Issue 10, 2013, Pages 2987-2997

  Andersen, Brian M ^a   Pluhar, G Elizabeth ^e   Seiler, Charles E ^e   Goulart, Michelle R ^e   SantaCruz, Karen S ^b   Schutten, Melissa M ^d,f   Meints, Joyce P ^b   O'Sullivan, M Gerard ^d,f   Bentley, R Timothy ^e   Packer, Rebecca A ^e,g   Thomovsky, Stephanie A ^h   Chen, Annie V ^h   Faissler, Dominik ⁱ   Chen, Wei ^a   Hunt, Matthew A ^c   Olin, Michael R ^a   Ohlfest, John R ^a,c  

^a UMHC   (United States)

^b Laboratory Medicine and Pathology   (United States)

^c Departments of Neurosurgery   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Departments of Veterinary   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g PURDUE UNIVERSITY   (United States)

^h WASHINGTON STATE UNIVERSITY   (United States)

ⁱ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL ANTIGEN; CHAPERONIN 60; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMIQUIMOD; MEMBRANE ANTIGEN; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MENINGIOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; TUMOR GROWTH; TUMOR INVASION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BRAIN; CANCER VACCINES; DOG DISEASES; DOGS; MENINGEAL NEOPLASMS; MENINGIOMA; VACCINATION;

EID: 84877869179     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3366     Document Type: Article

References (37)

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Hinsdale, IL: Available from: Http://www.cbtrus.org: Central Brain Tumor Registry of the United States; 2012.
2. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP. Opportunities for clinical research in meningioma. J Neurooncol 2010;99: 417-22.
3. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, et al. Hitting a moving target: Evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 2008;24:E3.
4. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D. The accuracy of meningioma grading: A 10-year retrospective audit. Neuropathol Appl Neurobiol 2005;31:141-9. (Pubitemid 40444915)
5. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 2012;107:315-21.
6. Soyuer S, Chang EL, Selek U, Shi W, Maor MH, DeMonte F. Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 2004;71:85-90. (Pubitemid 38452906)
7. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009;64:56-60.
8. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: A retrospective case series. J Neurooncol 2011;104:765-71.
9. Jung HW, Yoo H, Paek SH, Choi KS. Long-term outcome and growth rate of subtotally resected petroclival meningiomas: Experience with 38 cases. Neurosurgery 2000;46:567-74.
10. Perry A. Meningiomas. In:McLendon R, Rosenblum M, editors. Russell & Rubinstein's pathology of tumors of the nervous system. 7th ed. London, United Kingdom: Hodder Arnold; 2006. p. 427-74.
11. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010;99:393-405.
12. Perry A. Unmasking the secrets of meningioma: A slow but rewarding journey. Surg Neurol 2004;61:171-3. (Pubitemid 38147500)
13. Snyder JM, Shofer FS, Van Winkle TJ, Massicotte C. Canine intracranial primary neoplasia: 173 cases (1986-2003). J Vet Intern Med 2006; 20:669-75. (Pubitemid 43774117)
14. Adamo PF, Cantile C, Steinberg H. Evaluation of progesterone and estrogen receptor expression in 15 meningiomas of dogs and cats.Am J Vet Res 2003;64:1310-8. (Pubitemid 37236085)
15. Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F, et al. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. J Vet Intern Med 2006;20:663-8. (Pubitemid 43774116)
16. Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, et al. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol 2009;46:884-92.
17. Sturges BK, Dickinson PJ, Bollen AW, Koblik PD, Kass PH, Kortz GD, et al. Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med 2008;22: 586-95.
18. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56. (Pubitemid 351161319)
19. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.
20. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-15.
21. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-95.
22. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol 2007;28:5-11. (Pubitemid 46001619)
23. Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007;30:789-97. (Pubitemid 350295357)
24. Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010;28:3371-8.
25. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: An open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009;7:E58-65.
26. Pashenkov M, Goess G, Wagner C, Hörmann M, Jandl T, Moser A, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24: 5716-24. (Pubitemid 46631314)
27. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NYESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
28. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
29. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: An analysis of histologic parameters. Am J Surg Pathol 1997;21:1455-65. (Pubitemid 27528256)
30. Louis OH, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: IARC Press; 2007.
31. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66:739-53.
32. Burgoon MP, KeaysKM, OwensGP, Ritchie AM, Rai PR, Cool CD, et al. Laser-capture microdissection of plasma cells from subacute sclerosing panencephalitis brain reveals intrathecal disease-relevant antibodies. Proc Natl Acad Sci U S A 2005;102:7245-50. (Pubitemid 40696364)
33. American Veterinary Medical Association. U.S. Pet Ownership & Demographics Sourcebook; 2007.
34. Axlund TW, McGlasson ML, Smith AN. Surgery alone or in combination with radiation therapy for treatment of intracranial meningiomas in dogs: 31 cases (1989-2002). J Am Vet Med Assoc 2002;221: 1597-600. (Pubitemid 35388102)
35. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003;278:7607-16. (Pubitemid 36800769)
36. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. Bcell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88. (Pubitemid 351240747)
37. Daga A, Orengo AM, Gangemi RM, Marubbi D, Perera M, Comes A, et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 2007; 121:1756-63. (Pubitemid 47417294)